Pulmonary Hypertension Complicating Interstitial Lung Disease and COPD

Abstract

Pulmonary hypertension (PH) may complicate parenchymal lung disease, specifically interstitial lung diseases and chronic obstructive pulmonary disease, and uniformly increases the mortality risk. The epidemiology and degree of PH is variable and unique to the underlying lung disease. The clinician should exercise a high index of suspicion for PH complicating parenchymal lung disease especially given the nonspecific symptomatology and the limitations of echocardiography in this patient population. In general, PH-specific therapies in this setting have been poorly studied, with concern for increased shunting and/or ventilation/perfusion (V/Q) mismatch and resultant hypoxemia. A better understanding of the mechanisms underlying PH related to parenchymal lung disease may lead to novel pharmacological targets to prevent or treat this serious complication.

Keywords

interstitial lung disease - pulmonary hypertension - idiopathic pulmonary fibrosis - sarcoidosis - chronic obstructive pulmonary disease

• References

• 1 Nadrous HF, Pellikka PA, Krowka MJ , et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest 2005; 128 (4) 2393-2399
• 2 Fell CD, Martinez FJ. The impact of pulmonary arterial hypertension on idiopathic pulmonary fibrosis. Chest 2007; 131 (3) 641-643
• 3 Nunes H, Humbert M, Capron F , et al. Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis. Thorax 2006; 61 (1) 68-74
• 4 Badesch DB, Tapson VF, McGoon MD , et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000; 132 (6) 425-434
• 5 Kuhn KP, Byrne DW, Arbogast PG, Doyle TP, Loyd JE, Robbins IM. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med 2003; 167 (4) 580-586
• 6 Trad S, Amoura Z, Beigelman C , et al. Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum 2006; 54 (1) 184-191
• 7 Launay D, Sitbon O, Le Pavec J , et al. Long-term outcome of systemic sclerosis-associated pulmonary arterial hypertension treated with bosentan as first-line monotherapy followed or not by the addition of prostanoids or sildenafil. Rheumatology (Oxford) 2010; 49 (3) 490-500
• 8 Fartoukh M, Humbert M, Capron F , et al. Severe pulmonary hypertension in histiocytosis X. Am J Respir Crit Care Med 2000; 161 (1) 216-223
• 9 Le Pavec J, Lorillon G, Jaïs X , et al. Pulmonary Langerhans cell histiocytosis-associated pulmonary hypertension: clinical characteristics and impact of pulmonary arterial hypertension therapies. Chest 2012; 142 (5) 1150-1157
• 10 Meraj R, Wikenheiser-Brokamp KA, Young LR, McCormack FX. Lymphangioleiomyomatosis: new concepts in pathogenesis, diagnosis, and treatment. Semin Respir Crit Care Med 2012; 33 (5) 486-497
• 11 Cottin V, Harari S, Humbert M , et al; Groupe d'Etudes et de Recherche sur les Maladies “Orphelines” Pulmonaires (GERM”O”P). Pulmonary hypertension in lymphangioleiomyomatosis: characteristics in 20 patients. Eur Respir J 2012; 40 (3) 630-640
• 12 Lettieri CJ, Nathan SD, Barnett SD, Ahmad S, Shorr AF. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest 2006; 129 (3) 746-752
• 13 Shorr AF, Davies DB, Nathan SD. Outcomes for patients with sarcoidosis awaiting lung transplantation. Chest 2002; 122 (1) 233-238
• 14 Strange C, Highland KB. Pulmonary hypertension in interstitial lung disease. Curr Opin Pulm Med 2005; 11 (5) 452-455
• 15 Chaouat A, Bugnet AS, Kadaoui N , et al. Severe pulmonary hypertension and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172 (2) 189-194
• 16 Saggar R, Saggar R, Aboulhosn J, Belperio JA, Zisman DA, Lynch III JP. Diagnosis and hemodynamic assessment of pulmonary arterial hypertension. Semin Respir Crit Care Med 2009; 30 (4) 399-410
• 17 Hoeper MM, Lee SH, Voswinckel R , et al. Complications of right heart catheterization procedures in patients with pulmonary hypertension in experienced centers. J Am Coll Cardiol 2006; 48 (12) 2546-2552
• 18 Arcasoy SM, Christie JD, Ferrari VA , et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med 2003; 167 (5) 735-740
• 19 Nathan SD, Shlobin OA, Barnett SD , et al. Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in idiopathic pulmonary fibrosis. Respir Med 2008; 102 (9) 1305-1310
• 20 Zisman DA, Ross DJ, Belperio JA , et al. Prediction of pulmonary hypertension in idiopathic pulmonary fibrosis. Respir Med 2007; 101 (10) 2153-2159
• 21 Rich JD, Shah SJ, Swamy RS, Kamp A, Rich S. Inaccuracy of Doppler echocardiographic estimates of pulmonary artery pressures in patients with pulmonary hypertension: implications for clinical practice. Chest 2011; 139 (5) 988-993
• 22 Adkins JM, Collard HR. Idiopathic pulmonary fibrosis. Semin Respir Crit Care Med 2012; 33 (5) 433-439
• 23 Raghu G, Collard HR, Egan JJ , et al; ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011; 183 (6) 788-824
• 24 Lynch III JP, Saggar R, Weigt SS, Zisman DA, White ES. Usual interstitial pneumonia. Semin Respir Crit Care Med 2006; 27 (6) 634-651
• 25 Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006; 174 (7) 810-816
• 26 Gribbin J, Hubbard RB, Le Jeune I, Smith CJ, West J, Tata LJ. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax 2006; 61 (11) 980-985
• 27 Whelan TP, Dunitz JM, Kelly RF , et al. Effect of preoperative pulmonary artery pressure on early survival after lung transplantation for idiopathic pulmonary fibrosis. J Heart Lung Transplant 2005; 24 (9) 1269-1274
• 28 Lynch III JP, Saggar R, Weigt SS, Ross DJ, Belperio JA. Overview of lung transplantation and criteria for selection of candidates. Semin Respir Crit Care Med 2006; 27 (5) 441-469
• 29 Simonneau G, Galiè N, Rubin LJ , et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004; 43 (12, Suppl S ): 5S-12S
• 30 Lederer DJ, Arcasoy SM, Wilt JS, D'Ovidio F, Sonett JR, Kawut SM. Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2006; 174 (6) 659-664
• 31 Nathan SD, Shlobin OA, Ahmad S, Urbanek S, Barnett SD. Pulmonary hypertension and pulmonary function testing in idiopathic pulmonary fibrosis. Chest 2007; 131 (3) 657-663
• 32 Patel NM, Lederer DJ, Borczuk AC, Kawut SM. Pulmonary hypertension in idiopathic pulmonary fibrosis. Chest 2007; 132 (3) 998-1006
• 33 Shorr AF, Wainright JL, Cors CS, Lettieri CJ, Nathan SD. Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. Eur Respir J 2007; 30 (4) 715-721
• 34 Nathan S, Saggar R . III JL. Lung transplantation for interstitial lung disorders. In: Lynch III JP, Ross DJ, , eds. Lung and Heart-Lung Transplantation. New York, NY: Taylor & Francis Group; 2006: 165-204
• 35 Colombat M, Mal H, Groussard O , et al. Pulmonary vascular lesions in end-stage idiopathic pulmonary fibrosis: Histopathologic study on lung explant specimens and correlations with pulmonary hemodynamics. Hum Pathol 2007; 38 (1) 60-65
• 36 Cassan SM, Divertie MB, Brown Jr AL. Fine structural morphometry on biopsy specimens of human lung. 2. Diffuse idiopathic pulmonary fibrosis. Chest 1974; 65 (3) 275-278
• 37 Leach RM, Treacher DF. Clinical aspects of hypoxic pulmonary vasoconstriction. Exp Physiol 1995; 80 (5) 865-875
• 38 Wood JG, Johnson JS, Mattioli LF, Gonzalez NC. Systemic hypoxia increases leukocyte emigration and vascular permeability in conscious rats. J Appl Physiol 2000; 89 (4) 1561-1568
• 39 Turner-Warwick M. Precapillary systemic-pulmonary anastomoses. Thorax 1963; 18: 225-237
• 40 Keane MP, Belperio JA, Burdick MD, Lynch JP, Fishbein MC, Strieter RM. ENA-78 is an important angiogenic factor in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2001; 164 (12) 2239-2242
• 41 Keane MP, Arenberg DA, Lynch III JP , et al. The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J Immunol 1997; 159 (3) 1437-1443
• 42 Renzoni EA, Walsh DA, Salmon M , et al. Interstitial vascularity in fibrosing alveolitis. Am J Respir Crit Care Med 2003; 167 (3) 438-443
• 43 Wright L, Tuder RM, Wang J, Cool CD, Lepley RA, Voelkel NF. 5-Lipoxygenase and 5-lipoxygenase activating protein (FLAP) immunoreactivity in lungs from patients with primary pulmonary hypertension. Am J Respir Crit Care Med 1998; 157 (1) 219-229
• 44 Charbeneau RP, Peters-Golden M. Eicosanoids: mediators and therapeutic targets in fibrotic lung disease. Clin Sci (Lond) 2005; 108 (6) 479-491
• 45 Uguccioni M, Pulsatelli L, Grigolo B , et al. Endothelin-1 in idiopathic pulmonary fibrosis. J Clin Pathol 1995; 48 (4) 330-334
• 46 Giaid A, Michel RP, Stewart DJ, Sheppard M, Corrin B, Hamid Q. Expression of endothelin-1 in lungs of patients with cryptogenic fibrosing alveolitis. Lancet 1993; 341 (8860) 1550-1554
• 47 Hoeper MM, Galiè N, Simonneau G, Rubin LJ. New treatments for pulmonary arterial hypertension. Am J Respir Crit Care Med 2002; 165 (9) 1209-1216
• 48 Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351 (14) 1425-1436
• 49 Langleben D. Endothelin receptor antagonists in the treatment of pulmonary arterial hypertension. Clin Chest Med 2007; 28 (1) 117-125 , viii
• 50 Tuder RM, Cool CD, Geraci MW , et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999; 159 (6) 1925-1932
• 51 Zisman DA, Karlamangla AS, Kawut SM , et al. Validation of a method to screen for pulmonary hypertension in advanced idiopathic pulmonary fibrosis. Chest 2008; 133 (3) 640-645
• 52 Ghanem MK, Makhlouf HA, Agmy GR, Imam HM, Fouad DA. Evaluation of recently validated non- invasive formula using basic lung functions as new screening tool for pulmonary hypertension in idiopathic pulmonary fibrosis patients. Ann Thorac Med 2009; 4 (4) 187-196
• 53 Modrykamien AM, Gudavalli R, McCarthy K, Parambil J. Echocardiography, 6-minute walk distance, and distance-saturation product as predictors of pulmonary arterial hypertension in idiopathic pulmonary fibrosis. Respir Care 2010; 55 (5) 584-588
• 54 Swigris JJ, Olson AL, Shlobin OA, Ahmad S, Brown KK, Nathan SD. Heart rate recovery after six-minute walk test predicts pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respirology 2011; 16 (3) 439-445
• 55 Boutou AK, Pitsiou GG, Trigonis I , et al. Exercise capacity in idiopathic pulmonary fibrosis: the effect of pulmonary hypertension. Respirology 2011; 16 (3) 451-458
• 56 Devaraj A, Wells AU, Meister MG, Corte TJ, Hansell DM. The effect of diffuse pulmonary fibrosis on the reliability of CT signs of pulmonary hypertension. Radiology 2008; 249 (3) 1042-1049
• 57 Tan RT, Kuzo R, Goodman LR, Siegel R, Haasler GB, Presberg KW. Medical College of Wisconsin Lung Transplant Group. Utility of CT scan evaluation for predicting pulmonary hypertension in patients with parenchymal lung disease. Chest 1998; 113 (5) 1250-1256
• 58 Murray TI, Boxt LM, Katz J, Reagan K, Barst RJ. Estimation of pulmonary artery pressure in patients with primary pulmonary hypertension by quantitative analysis of magnetic resonance images. J Thorac Imaging 1994; 9 (3) 198-204
• 59 Nagaya N, Nishikimi T, Okano Y , et al. Plasma brain natriuretic peptide levels increase in proportion to the extent of right ventricular dysfunction in pulmonary hypertension. J Am Coll Cardiol 1998; 31 (1) 202-208
• 60 Krüger S, Graf J, Kunz D, Stickel T, Hanrath P, Janssens U. brain natriuretic peptide levels predict functional capacity in patients with chronic heart failure. J Am Coll Cardiol 2002; 40 (4) 718-722
• 61 Leuchte HH, Neurohr C, Baumgartner R , et al. Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 2004; 170 (4) 360-365
• 62 Leuchte HH, Baumgartner RA, Nounou ME , et al. Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am J Respir Crit Care Med 2006; 173 (7) 744-750
• 63 Corte TJ, Wort SJ, Gatzoulis MA , et al. Elevated brain natriuretic peptide predicts mortality in interstitial lung disease. Eur Respir J 2010; 36 (4) 819-825
• 64 Song JW, Song JK, Kim DS. Echocardiography and brain natriuretic peptide as prognostic indicators in idiopathic pulmonary fibrosis. Respir Med 2009; 103 (2) 180-186
• 65 Verma G, Marras T, Chowdhury N, Singer L. Health-related quality of life and 6.  min walk distance in patients with idiopathic pulmonary fibrosis. Can Respir J 2011; 18 (5) 283-287
• 66 Lederer DJ, Caplan-Shaw CE, O'Shea MK , et al. Racial and ethnic disparities in survival in lung transplant candidates with idiopathic pulmonary fibrosis. Am J Transplant 2006; 6 (2) 398-403
• 67 Lederer DJ, Arcasoy SM, Barr RG , et al. Racial and ethnic disparities in idiopathic pulmonary fibrosis: A UNOS/OPTN database analysis. Am J Transplant 2006; 6 (10) 2436-2442
• 68 Hamada K, Nagai S, Tanaka S , et al. Significance of pulmonary arterial pressure and diffusion capacity of the lung as prognosticator in patients with idiopathic pulmonary fibrosis. Chest 2007; 131 (3) 650-656
• 69 Alam S, Palevsky HI. Standard therapies for pulmonary arterial hypertension. Clin Chest Med 2007; 28 (1) 91-115 , viii
• 70 O'Callaghan DS, Gaine SP. Combination therapy and new types of agents for pulmonary arterial hypertension. Clin Chest Med 2007; 28 (1) 169-185 , ix
• 71 Galiè N, Torbicki A, Barst R , et al; Task Force. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. Eur Heart J 2004; 25 (24) 2243-2278
• 72 Galiè N, Hoeper MM, Humbert M , et al; ESC Committee for Practice Guidelines (CPG). Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30 (20) 2493-2537
• 73 Pitsiou G, Papakosta D, Bouros D. Pulmonary hypertension in idiopathic pulmonary fibrosis: a review. Respiration 2011; 82 (3) 294-304
• 74 Olschewski H, Ghofrani HA, Walmrath D , et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med 1999; 160 (2) 600-607
• 75 Ghofrani HA, Wiedemann R, Rose F , et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002; 360 (9337) 895-900
• 76 Collard HR, Anstrom KJ, Schwarz MI, Zisman DA. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest 2007; 131 (3) 897-899
• 77 Han MK, Bach DS, Hagan P , et al. Sildenafil Preserves Exercise Capacity in IPF Patients with Right Ventricular Dysfunction. Chest 2013; ;(Jan): 24
• 78 Zisman DA, Schwarz M, Anstrom KJ, Collard HR, Flaherty KR, Hunninghake GW. Idiopathic Pulmonary Fibrosis Clinical Research Network. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med 2010; 363 (7) 620-628
• 79 Corte TJ, Gatzoulis MA, Parfitt L, Harries C, Wells AU, Wort SJ. The use of sildenafil to treat pulmonary hypertension associated with interstitial lung disease. Respirology 2010; 15 (8) 1226-1232
• 80 Raghu G, King Jr TE, Behr J , et al. Quality of life and dyspnoea in patients treated with bosentan for idiopathic pulmonary fibrosis (BUILD-1). Eur Respir J 2010; 35 (1) 118-123
• 81 King Jr TE, Behr J, Brown KK , et al. BUILD-1: a randomized placebo-controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2008; 177 (1) 75-81
• 82 King Jr TE, Brown KK, Raghu G , et al. BUILD-3: a randomized, controlled trial of bosentan in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 184 (1) 92-99
• 83 Saggar R, Ross D, Lynch III J, Faul JL. Pulmonary arterial hypertension and lung transplantation. In: Lynch III JP, Ross DJ, , eds. Lung and Heart-Lung Transplantation . New York, NY: Taylor & Francis Group; 2006: 147-165
• 84 Whitson BA, Nath DS, Johnson AC , et al. Risk factors for primary graft dysfunction after lung transplantation. J Thorac Cardiovasc Surg 2006; 131 (1) 73-80
• 85 Thabut G, Vinatier I, Stern JB , et al. Primary graft failure following lung transplantation: predictive factors of mortality. Chest 2002; 121 (6) 1876-1882
• 86 Christie JD, Kotloff RM, Pochettino A , et al. Clinical risk factors for primary graft failure following lung transplantation. Chest 2003; 124 (4) 1232-1241
• 87 Fang A, Studer S, Kawut SM , et al; Lung Transplant Outcomes Group. Elevated pulmonary artery pressure is a risk factor for primary graft dysfunction following lung transplantation for idiopathic pulmonary fibrosis. Chest 2011; 139 (4) 782-787
• 88 Lynch III JP, Kazerooni EA, Gay SE. Pulmonary sarcoidosis. Clin Chest Med 1997; 18 (4) 755-785
• 89 Lynch III JP, Ma YL, Koss MN, White ES. Pulmonary sarcoidosis. Semin Respir Crit Care Med 2007; 28 (1) 53-74
• 90 Judson MA. Extrapulmonary sarcoidosis. Semin Respir Crit Care Med 2007; 28 (1) 83-101
• 91 Costabel U, Hunninghake GW. Sarcoidosis Statement Committee. American Thoracic Society. European Respiratory Society. World Association for Sarcoidosis and Other Granulomatous Disorders. ATS/ERS/WASOG statement on sarcoidosis. Eur Respir J 1999; 14 (4) 735-737
• 92 Shorr AF, Helman DL, Davies DB, Nathan SD. Sarcoidosis, race, and short-term outcomes following lung transplantation. Chest 2004; 125 (3) 990-996
• 93 Mitchell DN, Scadding JG. Sarcoidosis. Am Rev Respir Dis 1974; 110 (6) 774-802
• 94 Rizzato G, Pezzano A, Sala G , et al. Right heart impairment in sarcoidosis: haemodynamic and echocardiographic study. Eur J Respir Dis 1983; 64 (2) 121-128
• 95 Głuskowski J, Hawryłkiewicz I, Zych D, Wojtczak A, Zieliński J. Pulmonary haemodynamics at rest and during exercise in patients with sarcoidosis. Respiration 1984; 46 (1) 26-32
• 96 Battesti JP, Georges R, Basset F, Saumon G. Chronic cor pulmonale in pulmonary sarcoidosis. Thorax 1978; 33 (1) 76-84
• 97 Handa T, Nagai S, Miki S , et al. Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest 2006; 129 (5) 1246-1252
• 98 Sulica R, Teirstein AS, Kakarla S, Nemani N, Behnegar A, Padilla ML. Distinctive clinical, radiographic, and functional characteristics of patients with sarcoidosis-related pulmonary hypertension. Chest 2005; 128 (3) 1483-1489
• 99 Milman N, Burton CM, Iversen M, Videbaek R, Jensen CV, Carlsen J. Pulmonary hypertension in end-stage pulmonary sarcoidosis: therapeutic effect of sildenafil?. J Heart Lung Transplant 2008; 27 (3) 329-334
• 100 Arcasoy SM, Christie JD, Pochettino A , et al. Characteristics and outcomes of patients with sarcoidosis listed for lung transplantation. Chest 2001; 120 (3) 873-880
• 101 Shorr AF, Davies DB, Nathan SD. Predicting mortality in patients with sarcoidosis awaiting lung transplantation. Chest 2003; 124 (3) 922-928
• 102 Gluskowski J, Hawrylkiewicz I, Zych D, Zieliński J. Effects of corticosteroid treatment on pulmonary haemodynamics in patients with sarcoidosis. Eur Respir J 1990; 3 (4) 403-407
• 103 Shorr AF, Helman DL, Davies DB, Nathan SD. Pulmonary hypertension in advanced sarcoidosis: epidemiology and clinical characteristics. Eur Respir J 2005; 25 (5) 783-788
• 104 Baughman RP. Pulmonary hypertension associated with sarcoidosis. Arthritis Res Ther 2007; 9 (Suppl. 02) S8
• 105 Preston IR, Klinger JR, Landzberg MJ, Houtchens J, Nelson D, Hill NS. Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension. Chest 2001; 120 (3) 866-872
• 106 Rosen Y, Moon S, Huang CT, Gourin A, Lyons HA. Granulomatous pulmonary angiitis in sarcoidosis. Arch Pathol Lab Med 1977; 101 (4) 170-174
• 107 Takemura T, Matsui Y, Saiki S, Mikami R. Pulmonary vascular involvement in sarcoidosis: a report of 40 autopsy cases. Hum Pathol 1992; 23 (11) 1216-1223
• 108 Fahy GJ, Marwick T, McCreery CJ, Quigley PJ, Maurer BJ. Doppler echocardiographic detection of left ventricular diastolic dysfunction in patients with pulmonary sarcoidosis. Chest 1996; 109 (1) 62-66
• 109 Deng JC, Baughman RP, Lynch III JP. Cardiac involvement in sarcoidosis. Semin Respir Crit Care Med 2002; 23 (6) 513-527
• 110 Shlobin OA, Nathan SD. Management of end-stage sarcoidosis: pulmonary hypertension and lung transplantation. Eur Respir J 2012; 39 (6) 1520-1533
• 111 Emirgil C, Sobol BJ, Herbert WH, Trout K. The lesser circulation in pulmonary fibrosis secondary to sarcoidosis and its relationship to respiratory function. Chest 1971; 60 (4) 371-378
• 112 Baughman RP, Sparkman BK, Lower EE. Six-minute walk test and health status assessment in sarcoidosis. Chest 2007; 132 (1) 207-213
• 113 Bourbonnais JM, Samavati L. Clinical predictors of pulmonary hypertension in sarcoidosis. Eur Respir J 2008; 32 (2) 296-302
• 114 Baughman RP, Engel PJ, Taylor L, Lower EE. Survival in sarcoidosis-associated pulmonary hypertension: the importance of hemodynamic evaluation. Chest 2010; 138 (5) 1078-1085
• 115 Fisher KA, Serlin DM, Wilson KC, Walter RE, Berman JS, Farber HW. Sarcoidosis-associated pulmonary hypertension: outcome with long-term epoprostenol treatment. Chest 2006; 130 (5) 1481-1488
• 116 Olschewski H. Inhaled iloprost for the treatment of pulmonary hypertension. Eur Respir . Rev 2009; 18 (111) 29-34
• 117 Baughman RP, Judson MA, Lower EE , et al. Inhaled iloprost for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis 2009; 26 (2) 110-120
• 118 Baughman RP, Engel PJ, Meyer CA, Barrett AB, Lower EE. Pulmonary hypertension in sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2006; 23 (2) 108-116
• 119 Barnett CF, Bonura EJ, Nathan SD , et al. Treatment of sarcoidosis-associated pulmonary hypertension. A two-center experience. Chest 2009; 135 (6) 1455-1461
• 120 Foley RJ, Metersky ML. Successful treatment of sarcoidosis-associated pulmonary hypertension with bosentan. Respiration 2008; 75 (2) 211-214
• 121 Sharma S, Kashour T, Philipp R. Secondary pulmonary arterial hypertension: treated with endothelin receptor blockade. Tex Heart Inst J 2005; 32 (3) 405-410
• 122 Judson MA, Highland KB, Kwon S , et al. Ambrisentan for sarcoidosis associated pulmonary hypertension. Sarcoidosis Vasc Diffuse Lung Dis 2011; 28 (2) 139-145
• 123 Vassallo R, Ryu JH, Colby TV, Hartman T, Limper AH. Pulmonary Langerhans'-cell histiocytosis. N Engl J Med 2000; 342 (26) 1969-1978
• 124 Vassallo R, Ryu JH, Schroeder DR, Decker PA, Limper AH. Clinical outcomes of pulmonary Langerhans'-cell histiocytosis in adults. N Engl J Med 2002; 346 (7) 484-490
• 125 Tazi A. Adult pulmonary Langerhans' cell histiocytosis. Eur Respir J 2006; 27 (6) 1272-1285
• 126 Basset F, Corrin B, Spencer H , et al. Pulmonary histiocytosis X. Am Rev Respir Dis 1978; 118 (5) 811-820
• 127 Friedman PJ, Liebow AA, Sokoloff J. Eosinophilic granuloma of lung. Clinical aspects of primary histiocytosis in the adult. Medicine (Baltimore) 1981; 60 (6) 385-396
• 128 Chaowalit N, Pellikka PA, Decker PA , et al. Echocardiographic and clinical characteristics of pulmonary hypertension complicating pulmonary Langerhans cell histiocytosis. Mayo Clin Proc 2004; 79 (10) 1269-1275
• 129 Dauriat G, Mal H, Thabut G , et al. Lung transplantation for pulmonary Langerhans' cell histiocytosis: a multicenter analysis. Transplantation 2006; 81 (5) 746-750
• 130 Etienne B, Bertocchi M, Gamondes JP , et al. Relapsing pulmonary Langerhans cell histiocytosis after lung transplantation. Am J Respir Crit Care Med 1998; 157 (1) 288-291
• 131 Gabbay E, Dark JH, Ashcroft T , et al. Recurrence of Langerhans' cell granulomatosis following lung transplantation. Thorax 1998; 53 (4) 326-327
• 132 Harari S, Brenot F, Barberis M, Simmoneau G. Advanced pulmonary histiocytosis X is associated with severe pulmonary hypertension. Chest 1997; 111 (4) 1142-1144
• 133 Crausman RS, Jennings CA, Tuder RM, Ackerson LM, Irvin CG, King Jr TE. Pulmonary histiocytosis X: pulmonary function and exercise pathophysiology. Am J Respir Crit Care Med 1996; 153 (1) 426-435
• 134 Hamada K, Teramoto S, Narita N, Yamada E, Teramoto K, Kobzik L. Pulmonary veno-occlusive disease in pulmonary Langerhans' cell granulomatosis. Eur Respir J 2000; 15 (2) 421-423
• 135 Kiakouama L, Cottin V, Etienne-Mastroïanni B, Khouatra C, Humbert M, Cordier JF. Severe pulmonary hypertension in histiocytosis X: long-term improvement with bosentan. Eur Respir J 2010; 36 (1) 202-204
• 136 Benyounes B, Crestani B, Couvelard A, Vissuzaine C, Aubier M. Steroid-responsive pulmonary hypertension in a patient with Langerhans' cell granulomatosis (histiocytosis X). Chest 1996; 110 (1) 284-286
• 137 Ryu JH, Moss J, Beck GJ , et al; NHLBI LAM Registry Group. The NHLBI lymphangioleiomyomatosis registry: characteristics of 230 patients at enrollment. Am J Respir Crit Care Med 2006; 173 (1) 105-111
• 138 Johnson SR. Lymphangioleiomyomatosis. Eur Respir J 2006; 27 (5) 1056-1065
• 139 Johnson SR, Cordier JF, Lazor R , et al; Review Panel of the ERS LAM Task Force. European Respiratory Society guidelines for the diagnosis and management of lymphangioleiomyomatosis. Eur Respir J 2010; 35 (1) 14-26
• 140 Harknett EC, Chang WY, Byrnes S , et al. Use of variability in national and regional data to estimate the prevalence of lymphangioleiomyomatosis. QJM 2011; 104 (11) 971-979
• 141 Schiavina M, Di Scioscio V, Contini P , et al. Pulmonary lymphangioleiomyomatosis in a karyotypically normal man without tuberous sclerosis complex. Am J Respir Crit Care Med 2007; 176 (1) 96-98
• 142 Adriaensen ME, Schaefer-Prokop CM, Duyndam DA, Zonnenberg BA, Prokop M. Radiological evidence of lymphangioleiomyomatosis in female and male patients with tuberous sclerosis complex. Clin Radiol 2011; 66 (7) 625-628
• 143 Muzykewicz DA, Sharma A, Muse V, Numis AL, Rajagopal J, Thiele EA. TSC1 and TSC2 mutations in patients with lymphangioleiomyomatosis and tuberous sclerosis complex. J Med Genet 2009; 46 (7) 465-468
• 144 Matsui K, Tatsuguchi A, Valencia J , et al. Extrapulmonary lymphangioleiomyomatosis (LAM): clinicopathologic features in 22 cases. Hum Pathol 2000; 31 (10) 1242-1248
• 145 Avila NA, Kelly JA, Chu SC, Dwyer AJ, Moss J. Lymphangioleiomyomatosis: abdominopelvic CT and US findings. Radiology 2000; 216 (1) 147-153
• 146 Bernstein SM, Newell Jr JD, Adamczyk D, Mortenson RL, King Jr TE, Lynch DA. How common are renal angiomyolipomas in patients with pulmonary lymphangiomyomatosis?. Am J Respir Crit Care Med 1995; 152 (6, Pt 1) 2138-2143
• 147 Taveira-Dasilva AM, Rabel A, Gochuico BR, Avila NA, Moss J. Prevalence of uterine leiomyomas in lymphangioleiomyomatosis. Fertil Steril 2011; 96 (3) 711-714 , e1
• 148 Glasgow CG, Taveira-DaSilva A, Pacheco-Rodriguez G , et al. Involvement of lymphatics in lymphangioleiomyomatosis. Lymphat Res Biol 2009; 7 (4) 221-228
• 149 Taveira-DaSilva AM, Moss J. Optimizing treatments for lymphangioleiomyomatosis. Expert Rev Respir Med 2012; 6 (3) 267-276
• 150 Kitaichi M, Nishimura K, Itoh H, Izumi T. Pulmonary lymphangioleiomyomatosis: a report of 46 patients including a clinicopathologic study of prognostic factors. Am J Respir Crit Care Med 1995; 151 (2, Pt 1) 527-533
• 151 Taylor JR, Ryu J, Colby TV, Raffin TA. Lymphangioleiomyomatosis. Clinical course in 32 patients. N Engl J Med 1990; 323 (18) 1254-1260
• 152 Johnson SR, Tattersfield AE. Decline in lung function in lymphangioleiomyomatosis: relation to menopause and progesterone treatment. Am J Respir Crit Care Med 1999; 160 (2) 628-633
• 153 Taveira-DaSilva AM, Stylianou MP, Hedin CJ, Hathaway O, Moss J. Decline in lung function in patients with lymphangioleiomyomatosis treated with or without progesterone. Chest 2004; 126 (6) 1867-1874
• 154 Bissler JJ, McCormack FX, Young LR , et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med 2008; 358 (2) 140-151
• 155 McCormack FX, Inoue Y, Moss J , et al; National Institutes of Health Rare Lung Diseases Consortium; MILES Trial Group. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 2011; 364 (17) 1595-1606
• 156 Taveira-DaSilva AM, Hathaway O, Stylianou M, Moss J. Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus. Ann Intern Med 2011; 154 (12) 797-805 , W-292–W-293
• 157 Moua T, Olson EJ, Jean HC, Ryu JH. Resolution of chylous pulmonary congestion and respiratory failure in lymphangioleiomyomatosis with sirolimus therapy. Am J Respir Crit Care Med 2012; 186 (4) 389-390
• 158 Neurohr C, Hoffmann AL, Huppmann P , et al. Is sirolimus a therapeutic option for patients with progressive pulmonary lymphangioleiomyomatosis?. Respir Res 2011; 12: 66
• 159 Boehler A, Speich R, Russi EW, Weder W. Lung transplantation for lymphangioleiomyomatosis. N Engl J Med 1996; 335 (17) 1275-1280
• 160 Pechet TT, Meyers BF, Guthrie TJ , et al. Lung transplantation for lymphangioleiomyomatosis. J Heart Lung Transplant 2004; 23 (3) 301-308
• 161 Maurer JR, Ryu J, Beck G , et al; National Heart, Lung, and Blood Institute LAM Registry Study Group. Lung transplantation in the management of patients with lymphangioleiomyomatosis: baseline data from the NHLBI LAM Registry. J Heart Lung Transplant 2007; 26 (12) 1293-1299
• 162 Kpodonu J, Massad MG, Chaer RA , et al. The US experience with lung transplantation for pulmonary lymphangioleiomyomatosis. J Heart Lung Transplant 2005; 24 (9) 1247-1253
• 163 Taveira-DaSilva AM, Hathaway OM, Sachdev V, Shizukuda Y, Birdsall CW, Moss J. Pulmonary artery pressure in lymphangioleiomyomatosis: an echocardiographic study. Chest 2007; 132 (5) 1573-1578
• 164 Reynaud-Gaubert M, Mornex JF, Mal H , et al. Lung transplantation for lymphangioleiomyomatosis: the French experience. Transplantation 2008; 86 (4) 515-520
• 165 Harari S, Simonneau G, De Juli E , et al. Prognostic value of pulmonary hypertension in patients with chronic interstitial lung disease referred for lung or heart-lung transplantation. J Heart Lung Transplant 1997; 16 (4) 460-463
• 166 Simonneau G, Robbins IM, Beghetti M , et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009; 54 (1, Suppl): S43-S54
• 167 Walter RE, Wilk JB, Larson MG , et al. Systemic inflammation and COPD: the Framingham Heart Study. Chest 2008; 133 (1) 19-25
• 168 Cuttica MJ, Kalhan R, Shlobin OA , et al. Categorization and impact of pulmonary hypertension in patients with advanced COPD. Respir Med 2010; 104 (12) 1877-1882
• 169 Thabut G, Dauriat G, Stern JB , et al. Pulmonary hemodynamics in advanced COPD candidates for lung volume reduction surgery or lung transplantation. Chest 2005; 127 (5) 1531-1536
• 170 Andersen KH, Iversen M, Kjaergaard J , et al. Prevalence, predictors, and survival in pulmonary hypertension related to end-stage chronic obstructive pulmonary disease. J Heart Lung Transplant 2012; 31 (4) 373-380
• 171 Scharf SM, Iqbal M, Keller C, Criner G, Lee S, Fessler HE. National Emphysema Treatment Trial (NETT) Group. Hemodynamic characterization of patients with severe emphysema. Am J Respir Crit Care Med 2002; 166 (3) 314-322
• 172 Stevens D, Sharma K, Szidon P, Rich S, McLaughlin V, Kesten S. Severe pulmonary hypertension associated with COPD. Ann Transplant 2000; 5 (3) 8-12
• 173 Hugues T, Lemoigne F, Macone F, Cerboni P, Gibelin P. [Disproportionate pulmonary arterial hypertension and lung respiratory diseases: distinctive clinical, hemodynamic and prognosis of patients versus primary pulmonary arterial hypertension]. Ann Cardiol Angeiol (Paris) 2012; 61 (1) 1-7
• 174 Murray TR, Chen L, Marshall BE, Macarak EJ. Hypoxic contraction of cultured pulmonary vascular smooth muscle cells. Am J Respir Cell Mol Biol 1990; 3 (5) 457-465
• 175 Peinado VI, Santos S, Ramírez J, Roca J, Rodriguez-Roisin R, Barberà JA. Response to hypoxia of pulmonary arteries in chronic obstructive pulmonary disease: an in vitro study. Eur Respir J 2002; 20 (2) 332-338
• 176 Hales CA. The site and mechanism of oxygen sensing for the pulmonary vessels. Chest 1985; 88 (4, Suppl): 235S-240S
• 177 Meyrick B, Reid L. The effect of continued hypoxia on rat pulmonary arterial circulation. An ultrastructural study. Lab Invest 1978; 38 (2) 188-200
• 178 Barberà JA, Riverola A, Roca J , et al. Pulmonary vascular abnormalities and ventilation-perfusion relationships in mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1994; 149 (2, Pt 1) 423-429
• 179 Wright JL, Petty T, Thurlbeck WM. Analysis of the structure of the muscular pulmonary arteries in patients with pulmonary hypertension and COPD: National Institutes of Health nocturnal oxygen therapy trial. Lung 1992; 170 (2) 109-124
• 180 Matsuoka S, Washko GR, Yamashiro T , et al; National Emphysema Treatment Trial Research Group. Pulmonary hypertension and computed tomography measurement of small pulmonary vessels in severe emphysema. Am J Respir Crit Care Med 2010; 181 (3) 218-225
• 181 Butler J, Schrijen F, Henriquez A, Polu JM, Albert RK. Cause of the raised wedge pressure on exercise in chronic obstructive pulmonary disease. Am Rev Respir Dis 1988; 138 (2) 350-354
• 182 Schrijen FV, Henriquez A, Carton D, Delorme N, Butler J. Pulmonary vascular resistance rises with lung volume on exercise in obstructed airflow disease. Clin Physiol 1989; 9 (2) 143-150
• 183 Santos S, Peinado VI, Ramírez J , et al. Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD. Eur Respir J 2002; 19 (4) 632-638
• 184 Su Y, Han W, Giraldo C, De Li Y, Block ER. Effect of cigarette smoke extract on nitric oxide synthase in pulmonary artery endothelial cells. Am J Respir Cell Mol Biol 1998; 19 (5) 819-825
• 185 Yamato H, Sun JP, Churg A, Wright JL. Guinea pig pulmonary hypertension caused by cigarette smoke cannot be explained by capillary bed destruction. J Appl Physiol 1997; 82 (5) 1644-1653
• 186 Schiess R, Senn O, Fischler M , et al. Tobacco smoke: a risk factor for pulmonary arterial hypertension? A case-control study. Chest 2010; 138 (5) 1086-1092
• 187 Seimetz M, Parajuli N, Pichl A , et al. Inducible NOS inhibition reverses tobacco-smoke-induced emphysema and pulmonary hypertension in mice. Cell 2011; 147 (2) 293-305
• 188 Peinado VI, Barberá JA, Abate P , et al. Inflammatory reaction in pulmonary muscular arteries of patients with mild chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159 (5, Pt 1) 1605-1611
• 189 Chaouat A, Savale L, Chouaid C , et al. Role for interleukin-6 in COPD-related pulmonary hypertension. Chest 2009; 136 (3) 678-687
• 190 Churg A, Marshall CV, Sin DD , et al. Late intervention with a myeloperoxidase inhibitor stops progression of experimental chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 185 (1) 34-43
• 191 Wick MJ, Buesing EJ, Wehling CA , et al. Decreased neprilysin and pulmonary vascular remodeling in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2011; 183 (3) 330-340
• 192 Voelkel NF, Gomez-Arroyo J, Mizuno S. COPD/emphysema: The vascular story. Pulm Circ 2011; 1 (3) 320-326
• 193 Peinado VI, Barbera JA, Ramirez J , et al. Endothelial dysfunction in pulmonary arteries of patients with mild COPD. Am J Physiol 1998; 274 (6, Pt 1) L908-L913
• 194 Dinh-Xuan AT, Higenbottam TW, Clelland CA , et al. Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease. N Engl J Med 1991; 324 (22) 1539-1547
• 195 Noureddine H, Gary-Bobo G, Alifano M , et al. Pulmonary artery smooth muscle cell senescence is a pathogenic mechanism for pulmonary hypertension in chronic lung disease. Circ Res 2011; 109 (5) 543-553
• 196 Oswald-Mammosser M, Apprill M, Bachez P, Ehrhart M, Weitzenblum E. Pulmonary hemodynamics in chronic obstructive pulmonary disease of the emphysematous type. Respiration 1991; 58 (5-6) 304-310
• 197 Kiakouama L, Cottin V, Glerant JC, Bayle JY, Mornex JF, Cordier JF. Conditions associated with severe carbon monoxide diffusion coefficient reduction. Respir Med 2011; 105 (8) 1248-1256
• 198 Rizzato GF, Rampulla C, Mandelli V, Benza GC, Mantero O, Morpurgo M. Can pulmonary artery pressure be predicted without right heart catheterization in chronic obstructive lung disease?. Acta Cardiol 1975; 30 (4) 251-265
• 199 Sims MW, Margolis DJ, Localio AR, Panettieri RA, Kawut SM, Christie JD. Impact of pulmonary artery pressure on exercise function in severe COPD. Chest 2009; 136 (2) 412-419
• 200 Bishop JM, Cross KW. Use of other physiological variables to predict pulmonary arterial pressure in patients with chronic respiratory disease. Multicentre study. Eur Heart J 1981; 2 (6) 509-517
• 201 Ooi H, Cadogan E, Sweeney M, Howell K, O'Regan RG, McLoughlin P. Chronic hypercapnia inhibits hypoxic pulmonary vascular remodeling. Am J Physiol Heart Circ Physiol 2000; 278 (2) H331-H338
• 202 Hurdman J, Condliffe R, Elliot CA , et al. ASPIRE registry: assessing the Spectrum of Pulmonary hypertension Identified at a REferral centre. Eur Respir J 2012; 39 (4) 945-955
• 203 Burrows B, Kettel LJ, Niden AH, Rabinowitz M, Diener CF. Patterns of cardiovascular dysfunction in chronic obstructive lung disease. N Engl J Med 1972; 286 (17) 912-918
• 204 Oswald-Mammosser M, Weitzenblum E, Quoix E , et al. Prognostic factors in COPD patients receiving long-term oxygen therapy. Importance of pulmonary artery pressure. Chest 1995; 107 (5) 1193-1198
• 205 Weitzenblum E, Hirth C, Ducolone A, Mirhom R, Rasaholinjanahary J, Ehrhart M. Prognostic value of pulmonary artery pressure in chronic obstructive pulmonary disease. Thorax 1981; 36 (10) 752-758
• 206 Skwarski K, MacNee W, Wraith PK, Sliwinski P, Zielinski J. Predictors of survival in patients with chronic obstructive pulmonary disease treated with long-term oxygen therapy. Chest 1991; 100 (6) 1522-1527
• 207 Report of the Medical Research Council Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981; 1 (8222) 681-686
• 208 Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med 1980; 93 (3) 391-398
• 209 Keller R, Ragaz A, Borer P. Predictors for early mortality in patients with long-term oxygen home therapy. Respiration 1985; 48 (3) 216-221
• 210 Finlay M, Middleton HC, Peake MD, Howard P. Cardiac output, pulmonary hypertension, hypoxaemia and survival in patients with chronic obstructive airways disease. Eur J Respir Dis 1983; 64 (4) 252-263
• 211 Stone AC, Machan JT, Mazer J, Casserly B, Klinger JR. Echocardiographic evidence of pulmonary hypertension is associated with increased 1-year mortality in patients admitted with chronic obstructive pulmonary disease. Lung 2011; 189 (3) 207-212
• 212 Orens JB, Estenne M, Arcasoy S , et al; Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. International guidelines for the selection of lung transplant candidates: 2006 update—a consensus report from the Pulmonary Scientific Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2006; 25 (7) 745-755
• 213 Kessler R, Faller M, Fourgaut G, Mennecier B, Weitzenblum E. Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159 (1) 158-164
• 214 McGhan R, Radcliff T, Fish R, Sutherland ER, Welsh C, Make B. Predictors of rehospitalization and death after a severe exacerbation of COPD. Chest 2007; 132 (6) 1748-1755
• 215 Wells JM, Washko GR, Han MK , et al; COPDGene Investigators; ECLIPSE Study Investigators. Pulmonary arterial enlargement and acute exacerbations of COPD. N Engl J Med 2012; 367 (10) 913-921
• 216 Abraham AS, Cole RB, Green ID, Hedworth-Whitty RB, Clarke SW, Bishop JM. Factors contributing to the reversible pulmonary hypertension of patients with acute respiratory failure studies by serial observations during recovery. Circ Res 1969; 24 (1) 51-60
• 217 Akcay M, Yeter E, Durmaz T , et al. Treatment of acute chronic obstructive pulmonary disease exacerbation improves right ventricle function. Eur J Echocardiogr 2010; 11 (6) 530-536
• 218 Weitzenblum E, Schrijen F, Mohan-Kumar T, Colas des Francs V, Lockhart A. Variability of the pulmonary vascular response to acute hypoxia in chronic bronchitis. Chest 1988; 94 (4) 772-778
• 219 Fletcher EC, Levin DC. Cardiopulmonary hemodynamics during sleep in subjects with chronic obstructive pulmonary disease. The effect of short- and long-term oxygen. Chest 1984; 85 (1) 6-14
• 220 Raeside DA, Brown A, Patel KR, Welsh D, Peacock AJ. Ambulatory pulmonary artery pressure monitoring during sleep and exercise in normal individuals and patients with COPD. Thorax 2002; 57 (12) 1050-1053
• 221 Catterall JR, Douglas NJ, Calverley PM , et al. Transient hypoxemia during sleep in chronic obstructive pulmonary disease is not a sleep apnea syndrome. Am Rev Respir Dis 1983; 128 (1) 24-29
• 222 Sabit R, Bolton CE, Fraser AG , et al. Sub-clinical left and right ventricular dysfunction in patients with COPD. Respir Med 2010; 104 (8) 1171-1178
• 223 Oliver RM, Fleming JS, Waller DG. Right ventricular function at rest and during exercise in chronic obstructive pulmonary disease. Comparison of two radionuclide techniques. Chest 1993; 103 (1) 74-80
• 224 Pynnaert C, Lamotte M, Naeije R. Aerobic exercise capacity in COPD patients with and without pulmonary hypertension. Respir Med 2010; 104 (1) 121-126
• 225 Boerrigter BG, Bogaard HJ, Trip P , et al. Ventilatory and cardiocirculatory exercise profiles in COPD: the role of pulmonary hypertension. Chest 2012; 142 (5) 1166-1174
• 226 Fisher MR, Criner GJ, Fishman AP , et al; NETT Research Group. Estimating pulmonary artery pressures by echocardiography in patients with emphysema. Eur Respir J 2007; 30 (5) 914-921
• 227 Oswald-Mammosser M, Oswald T, Nyankiye E, Dickele MC, Grange D, Weitzenblum E. Non-invasive diagnosis of pulmonary hypertension in chronic obstructive pulmonary disease. Comparison of ECG, radiological measurements, echocardiography and myocardial scintigraphy. Eur J Respir Dis 1987; 71 (5) 419-429
• 228 Tramarin R, Torbicki A, Marchandise B, Laaban JP, Morpurgo M. Doppler echocardiographic evaluation of pulmonary artery pressure in chronic obstructive pulmonary disease. A European multicentre study. Working Group on Noninvasive Evaluation of Pulmonary Artery Pressure. European Office of the World Health Organization, Copenhagen. Eur Heart J 1991; 12 (2) 103-111
• 229 Chi SY, Kim EY, Ban HJ , et al. Plasma N-terminal pro-brain natriuretic peptide: a prognostic marker in patients with chronic obstructive pulmonary disease. Lung 2012; 190 (3) 271-276
• 230 Weitzenblum E, Sautegeau A, Ehrhart M, Mammosser M, Hirth C, Roegel E. Long-term course of pulmonary arterial pressure in chronic obstructive pulmonary disease. Am Rev Respir Dis 1984; 130 (6) 993-998
• 231 Kessler R, Faller M, Weitzenblum E , et al. “Natural history” of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease. Am J Respir Crit Care Med 2001; 164 (2) 219-224
• 232 Rizkallah J, Man SF, Sin DD. Prevalence of pulmonary embolism in acute exacerbations of COPD: a systematic review and metaanalysis. Chest 2009; 135 (3) 786-793
• 233 Rao BS, Cohn KE, Eldridge FE, Hancock EW. Left ventricular failure secondary to chronic pulmonary disease. Aspen Emphysema Conf 1968; 11: 129-134
• 234 Barr RG, Bluemke DA, Ahmed FS , et al. Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med 2010; 362 (3) 217-227
• 235 Watz H, Waschki B, Meyer T , et al. Decreasing cardiac chamber sizes and associated heart dysfunction in COPD: role of hyperinflation. Chest 2010; 138 (1) 32-38
• 236 Anderson WJ, Lipworth BJ. Relationships between impulse oscillometry, spirometry and dyspnoea in COPD. J R Coll Physicians Edinb 2012; 42 (2) 111-115
• 237 Wiggins J, Strickland B, Turner-Warwick M. Combined cryptogenic fibrosing alveolitis and emphysema: the value of high resolution computed tomography in assessment. Respir Med 1990; 84 (5) 365-369
• 238 Hiwatari N, Shimura S, Takishima T. Pulmonary emphysema followed by pulmonary fibrosis of undetermined cause. Respiration 1993; 60 (6) 354-358
• 239 Doherty MJ, Pearson MG, O'Grady EA, Pellegrini V, Calverley PM. Cryptogenic fibrosing alveolitis with preserved lung volumes. Thorax 1997; 52 (11) 998-1002
• 240 Aduen JF, Zisman DA, Mobin SI , et al. Retrospective study of pulmonary function tests in patients presenting with isolated reduction in single-breath diffusion capacity: implications for the diagnosis of combined obstructive and restrictive lung disease. Mayo Clin Proc 2007; 82 (1) 48-54
• 241 Mejía M, Carrillo G, Rojas-Serrano J , et al. Idiopathic pulmonary fibrosis and emphysema: decreased survival associated with severe pulmonary arterial hypertension. Chest 2009; 136 (1) 10-15
• 242 Jankowich MD, Rounds S. Combined pulmonary fibrosis and emphysema alters physiology but has similar mortality to pulmonary fibrosis without emphysema. Lung 2010; 188 (5) 365-373
• 243 Akagi T, Matsumoto T, Harada T , et al. Coexistent emphysema delays the decrease of vital capacity in idiopathic pulmonary fibrosis. Respir Med 2009; 103 (8) 1209-1215
• 244 Kurashima K, Takayanagi N, Tsuchiya N , et al. The effect of emphysema on lung function and survival in patients with idiopathic pulmonary fibrosis. Respirology 2010; 15 (5) 843-848
• 245 Todd NW, Jeudy J, Lavania S , et al. Centrilobular emphysema combined with pulmonary fibrosis results in improved survival. Fibrogenesis Tissue Repair 2011; 4 (1) 6
• 246 Cottin V, Nunes H, Brillet PY , et al; Groupe d'Etude et de Recherche sur les Maladies Orphelines Pulmonaires (GERM O P). Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J 2005; 26 (4) 586-593
• 247 Cottin V, Le Pavec J, Prévot G , et al; GERM”O”P. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J 2010; 35 (1) 105-111
• 248 Morrell NW, Sarybaev AS, Alikhan A, Mirrakhimov MM, Aldashev AA. ACE genotype and risk of high altitude pulmonary hypertension in Kyrghyz highlanders. Lancet 1999; 353 (9155) 814
• 249 van Suylen RJ, Wouters EF, Pennings HJ , et al. The DD genotype of the angiotensin converting enzyme gene is negatively associated with right ventricular hypertrophy in male patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159 (6) 1791-1795
• 250 Eddahibi S, Chaouat A, Morrell N , et al. Polymorphism of the serotonin transporter gene and pulmonary hypertension in chronic obstructive pulmonary disease. Circulation 2003; 108 (15) 1839-1844
• 251 Shaw JG, Dent AG, Passmore LH , et al. Genetic influences on right ventricular systolic pressure (RVSP) in chronic obstructive pulmonary disease (COPD). BMC Pulm Med 2012; 12: 25
• 252 Castaldi PJ, Cho MH, Cohn M , et al. The COPD genetic association compendium: a comprehensive online database of COPD genetic associations. Hum Mol Genet 2010; 19 (3) 526-534
• 253 Eddahibi S, Chaouat A, Tu L , et al. Interleukin-6 gene polymorphism confers susceptibility to pulmonary hypertension in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006; 3 (6) 475-476
• 254 Yildiz P, Oflaz H, Cine N, Erginel-Unaltuna N, Erzengin F, Yilmaz V. Gene polymorphisms of endothelial nitric oxide synthase enzyme associated with pulmonary hypertension in patients with COPD. Respir Med 2003; 97 (12) 1282-1288
• 255 Kanazawa H, Tateishi Y, Yoshikawa J. Acute effects of nifedipine administration in pulmonary haemodynamics and oxygen delivery during exercise in patients with chronic obstructive pulmonary disease: implication of the angiotensin-converting enzyme gene polymorphisms. Clin Physiol Funct Imaging 2004; 24 (4) 224-228
• 256 Kanazawa H, Hirata K, Yoshikawa J. Effects of captopril administration on pulmonary haemodynamics and tissue oxygenation during exercise in ACE gene subtypes in patients with COPD: a preliminary study. Thorax 2003; 58 (7) 629-631
• 257 Kanazawa H, Okamoto T, Hirata K, Yoshikawa J. Deletion polymorphisms in the angiotensin converting enzyme gene are associated with pulmonary hypertension evoked by exercise challenge in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 162 (4, Pt 1) 1235-1238
• 258 de Torres JP, Cote CG, López MV , et al. Sex differences in mortality in patients with COPD. Eur Respir J 2009; 33 (3) 528-535
• 259 Ekström MP, Jogréus C, Ström KE. Comorbidity and sex-related differences in mortality in oxygen-dependent chronic obstructive pulmonary disease. PLoS ONE 2012; 7 (4) e35806
• 260 Shimizu M, Imanishi J, Takano T, Miwa Y. Disproportionate pulmonary hypertension in a patient with early-onset pulmonary emphysema treated with specific drugs for pulmonary arterial hypertension. Intern Med 2011; 50 (20) 2341-2346
• 261 Dernaika TA, Beavin M, Kinasewitz GT. Iloprost improves gas exchange and exercise tolerance in patients with pulmonary hypertension and chronic obstructive pulmonary disease. Respiration 2010; 79 (5) 377-382
• 262 Barberà JA, Roger N, Roca J, Rovira I, Higenbottam TW, Rodriguez-Roisin R. Worsening of pulmonary gas exchange with nitric oxide inhalation in chronic obstructive pulmonary disease. Lancet 1996; 347 (8999) 436-440
• 263 Vonbank K, Ziesche R, Higenbottam TW , et al. Controlled prospective randomised trial on the effects on pulmonary haemodynamics of the ambulatory long term use of nitric oxide and oxygen in patients with severe COPD. Thorax 2003; 58 (4) 289-293
• 264 Blanco I, Gimeno E, Munoz PA , et al. Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am J Respir Crit Care Med 2010; 181 (3) 270-278
• 265 Holverda S, Rietema H, Bogaard HJ , et al. Acute effects of sildenafil on exercise pulmonary hemodynamics and capacity in patients with COPD. Pulm Pharmacol Ther 2008; 21 (3) 558-564
• 266 Lederer DJ, Bartels MN, Schluger NW , et al. Sildenafil for chronic obstructive pulmonary disease: a randomized crossover trial. COPD 2012; 9 (3) 268-275
• 267 Namendys-Silva SA, Hernández-Garay M. Should we administer sildenafil to patients with obstructive pulmonary disease and pulmonary hypertension? No. Am J Respir Crit Care Med 2010; 182 (9) 1206 , author reply 1206–1207
• 268 Kim HS, Park JH, Park SJ, Park JK, Lee HB. Use of tadalafil for treating pulmonary arterial hypertension secondary to chronic obstructive pulmonary disease. Korean J Intern Med 2007; 22 (1) 37-39
• 269 Park JS, Lim HJ, Cho YJ, Lee JH, Yoon HI, Lee CT. Udenafil improves exercise capacity in patients with chronic obstructive pulmonary disease: a prospective study. COPD 2012; 9 (5) 499-504
• 270 Stolz D, Rasch H, Linka A , et al. A randomised, controlled trial of bosentan in severe COPD. Eur Respir J 2008; 32 (3) 619-628
• 271 Mercurio V, Carlomagno G, Fazio S. Response to pulmonary vasodilator treatment in a former smoker with combined interstitial lung disease complicated by pulmonary hypertension: case report and review of the literature. Heart Lung 2012; 41 (5) 512-517
• 272 Reed RM, Iacono A, DeFilippis A , et al. Statin therapy is associated with decreased pulmonary vascular pressures in severe COPD. COPD 2011; 8 (2) 96-102
• 273 Wright JL, Zhou S, Preobrazhenska O , et al. Statin reverses smoke-induced pulmonary hypertension and prevents emphysema but not airway remodeling. Am J Respir Crit Care Med 2011; 183 (1) 50-58
• 274 Wu D, Lee D, Sung YK. Prospect of vasoactive intestinal peptide therapy for COPD/PAH and asthma: a review. Respir Res 2011; 12: 45
• 275 Zakynthinos E, Daniil Z, Papanikolaou J, Makris D. Pulmonary hypertension in COPD: pathophysiology and therapeutic targets. Curr Drug Targets 2011; 12 (4) 501-513
• 276 Barberà JA, Peinado VI. Vascular progenitor cells in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2011; 8 (6) 528-534
• 277 Dumas de La Roque E, Savineau JP, Metivier AC , et al. Dehydroepiandrosterone (DHEA) improves pulmonary hypertension in chronic obstructive pulmonary disease (COPD): a pilot study. Ann Endocrinol (Paris) 2012; 73 (1) 20-25